Targeted Genetics Corporation Announces Data From First Gene Therapy Trial for Leber's Congenital Amaurosis in The New England Journal of Medicine

FORT LAUDERDALE, FL and SEATTLE, WA--(Marketwire - April 27, 2008) - Targeted Genetics Corporation (NASDAQ: TGEN) today announced encouraging results from a Phase 1/2 clinical study demonstrating that treatment of three young adults with Leber's congenital amaurosis (LCA) with an Adeno-Associated Virus (AAV) vector containing the RPE 65 coding sequence resulted in improved visual function in one patient. The study, titled "Effect of Gene Therapy on Visual Function in Leber's Congenital Amaurosis," by Bainbridge, et al., conducted in collaboration with University College London and Moorfields Hospital, will appear in the May 22 issue of the New England Journal of Medicine.